Hartmut Michel from the Max Planck Institute of Biophysics has an editorial (open access!) in Angewandte Chemie with a title that makes his views clear: "The Nonsense of Biofuels". He essentially comes down hard on biofuel proponents of all stripes and not just the much hyped ethanol-from-corn lobby. Michel won the Nobel Prize for cracking open the structure of one of earth's most important proteins - the photosynthetic reaction center - so he certainly knows his photosynthesis.- Home
- Angry by Choice
- Catalogue of Organisms
- Chinleana
- Doc Madhattan
- Games with Words
- Genomics, Medicine, and Pseudoscience
- History of Geology
- Moss Plants and More
- Pleiotropy
- Plektix
- RRResearch
- Skeptic Wonder
- The Culture of Chemistry
- The Curious Wavefunction
- The Phytophactor
- The View from a Microbiologist
- Variety of Life
Field of Science
-
Overpopulation, Overconsumption, War: the Answer is Equality4 days ago in Pleiotropy
-
Change of address1 year ago in Variety of Life
-
Change of address1 year ago in Catalogue of Organisms
-
-
Earth Day: Pogo and our responsibility1 year ago in Doc Madhattan
-
What I Read 20241 year ago in Angry by Choice
-
I've moved to Substack. Come join me there.1 year ago in Genomics, Medicine, and Pseudoscience
-
-
-
-
Histological Evidence of Trauma in Dicynodont Tusks7 years ago in Chinleana
-
Posted: July 21, 2018 at 03:03PM8 years ago in Field Notes
-
Why doesn't all the GTA get taken up?8 years ago in RRResearch
-
-
Harnessing innate immunity to cure HIV10 years ago in Rule of 6ix
-
-
-
-
-
-
post doc job opportunity on ribosome biochemistry!11 years ago in Protein Evolution and Other Musings
-
Blogging Microbes- Communicating Microbiology to Netizens12 years ago in Memoirs of a Defective Brain
-
Re-Blog: June Was 6th Warmest Globally12 years ago in The View from a Microbiologist
-
-
-
The Lure of the Obscure? Guest Post by Frank Stahl14 years ago in Sex, Genes & Evolution
-
-
Lab Rat Moving House15 years ago in Life of a Lab Rat
-
Goodbye FoS, thanks for all the laughs15 years ago in Disease Prone
-
-
Slideshow of NASA's Stardust-NExT Mission Comet Tempel 1 Flyby15 years ago in The Large Picture Blog
-
in The Biology Files
The end of biofuels?
Hartmut Michel from the Max Planck Institute of Biophysics has an editorial (open access!) in Angewandte Chemie with a title that makes his views clear: "The Nonsense of Biofuels". He essentially comes down hard on biofuel proponents of all stripes and not just the much hyped ethanol-from-corn lobby. Michel won the Nobel Prize for cracking open the structure of one of earth's most important proteins - the photosynthetic reaction center - so he certainly knows his photosynthesis.Identifying new drug targets in zebrafish
Classically, when very little about molecular biology and protein structure was known, one of the best methods to discover drugs was to try to guess physiological effects by looking at drug similarity. The rationale was simple; drug A has this chemical structure and lowers blood pressure. Drug B which is being used for a completely different indication also has a similar chemical structure. Maybe we can use drug B for lowering blood pressure too?In the absence of rational approaches this technique (which these days is called "repurposing") could be surprisingly fruitful. However, as molecular biology, crystallography and structure-based drug design took off in the 80s, rational drug discovery became much more focused on protein structure and drug developers began trying to guess drug function by looking at target similarity in terms of sequences and binding pockets.
But the relative lack of dividends from structure-based drug design (which nonetheless continues to be important) has led to a re-examination of the old paradigm. One of the most interesting advances to come out of this thinking was pioneered by Brian Shoichet and Bryan Roth's groups (at UCSF and UNC-Chapel Hill) a few years back. Their rationale was simple too; look at drug similarity, albeit using modern computational methods and metrics, and try to cross-correlate drug targets using these similarity metrics. Similar drugs should hit each other's targets. The method seems somewhat crude but has worked surprisingly well. It was even listed as one of Wired magazine's top ten scientific breakthroughs of 2009.
In a recent publication the authors take the method a step further and apply it to phenotypic screening which has emerged as an increasingly popular method in the pharmaceutical industry. Phenotypic screening is attractive because it bypasses having knowledge of the exact molecular target; basically you just inject different potential drugs in a test system and look at the results which are usually quantified by a phenotypic response such as a change in membrane potential, cell differentiation or even something as general as locomotion. Once a particular compound has elicited a particular response, we can start the arduous task of finding out what it's doing at a molecular level. Not surprisingly, several proteins can be responsible for a general response like locomotion and detecting all of them is non-trivial to say the least. It is for this rather involved exercise that the authors provide a remarkably simple potential (partial) solution.
The current study looks at phenotypic screening on the zebrafish, a favorite model organism of biologists. 14,000 molecule were screened to elicit a photomotor response in the zebrafish embryos. Out of these, about 700 were deemed active. To find out the targets for these molecules, the authors interrogated their chemical "similarity" against a large group of compounds for which targets are known. Importantly, the authors use a statistical technique to calculate an expectation value (E value) which indicates whether the similarity arises by chance alone. A lower E value means a higher likelihood of statistical significance. One of the most remarkable things in these studies is that the metric for similarity is a simple, computationally cheap 2D metric called a fingerprint which looks at the presence or absence of certain functional groups in the molecules. That such a metric can work at all is remarkable because we know that an accurate estimation of similarity should ideally include the 3D conformation that the drug presents to the protein target.
Nonetheless, 284 molecules predicted to be active on 404 targets were picked based on their low E values. Out of these, 20 molecules were especially interesting because they were seen to have novel drug-target associations not seen before. When the authors tested these molecules against the relevant targets, 11 among them had activities ranging from low nanomolar to 10 µM. For a computational method this hit rate is quite impressive, although a more realistic measure of the hit rate would have come from testing all 284 compounds. The activity of the molecules was validated by running comparisons with molecules that were known to elicit the same response from the predicted targets. Confirmation also came from competition experiments with antagonists. Some of the unexpected targets predicted include the beta-adrenergic receptor, dopamine receptors and potassium ion channels.
I find these studies very encouraging. For one thing, the computational method can potentially save a huge amount of time needed to experimentally uncover the target for every active compound. As mentioned above, it's also remarkable that a very simple metric of 2D similarity yields useful results. The success rate is impressive; however, an even lower rate would still have been worth the modest effort if it resulted in new drug-target relationships (which are far more useful than new chemically similar ligands for the same target). However I do think it would have been very interesting to look at the failures. An obvious source of failure comes from using the wrong measure of similarity; at least some compounds are failing presumably because their 2D similarity does not translate to the 3D similarity in conformation required for binding to the protein target. In addition there could be protein flexibility which would result in very different binding for supposedly similar compounds. Medicinal chemists are well aware of "activity cliffs" where small differences in chemical structure lead to great differences in activity. These cliffs could also lead to lack of binding to a predicted target.
Nevertheless, in an age when drug discovery is only getting harder and phenotypic screening seems to be an increasingly important technique, these computational approaches promise to be a useful complement. Gratifyingly, the authors have developed a website where the algorithm is available for free. The technique has also spawned a startup.
Image source
Roald Hoffmann on the futility of classifying chemists
Roald Hoffmann has an editorial (open access!) in Angewandte Chemie in which he (mostly) gently scolds those who have criticized many of the last decade's Nobel Prizes as being "insufficiently chemical". I agree with him that any kind of preconceived expectations about who should get the Nobel Prize tries to fit chemistry into a straitjacket and denies scientists who may not have been trained in traditional chemistry departments the right to call themselves chemists."Ubiquitin and the ribosome, fluorescent proteins and ion channels are as fundamentally chemical as metal surfaces, enantioselective catalysts, olefin metathesis, or, just to name some fields squarely in our profession that should be (or should have been) recognized, laser chemistry, metal–metal multiple bonding, bioinorganic chemistry, oral contraception, and green or sustainable chemistry."
And ultimately he emphasizes something that we should all constantly remind each other. It's a prize, awarded by human beings. It's an honor all right, but it does very little to highlight the objective value of the research which is usually evident far before the actual recognition. The fact that we were informally nominating Robert Grubbs or Roger Tsien years before they received the prizes makes it clear that no prize was really going to change our perception of how important their work was. Today we look at Tsien's research on green fluorescent protein with the same joyful interest that we did ten years ago.
Hoffmann sees the principal function of the Nobel Prize as providing an incentive for young students and researchers from scientifically underprivileged countries, and he cites the examples of Kenichi Fukui and Ahmed Zewail inspiring their fellow countrymen. The Nobel Prize certainly serves this function, but I have always been a little wary of pitching the benefits of scientific research by citing any kind of prize. The fact is that most people who do interesting research will never win the Nobel Prize and this does nothing to undervalue the importance of their work. So even from a strictly statistical standpoint, it would continue to be much more fruitful to point out the real benefits of science to young people- as a means of understanding the world and having fun while you are at it. Prizes may or may not follow.
Hat tip: Excimer
Book review: Philip Anderson's "More and Different"
The Nobel Prize-winning physicist Philip Warren Anderson is one of those rare species - a scientist who is not only world-class in his own field but who seems capable of saying something interesting about virtually every topic under the sun. His career at Bell Labs overlapped with the lab's most illustrious period and apart from his prizewinning work in solid-state physics, Anderson has made groundbreaking contributions to at least two other diverse fields - particle physics (he was actually the first one to suggest the existence of the Higgs boson) and the epistemology of science. In this book he holds forth on a wide variety of subjects ranging from postmodernism to superconductivity. The chapters consist of book reviews, commemorative essays, transcripts of talks, opinion pieces and a variety of other writings over the past five decades. In every chapter there are at least a few rather deep statements which deserve close scrutiny.The book is roughly divided into three parts. The first part details Anderson's views on the history and philosophy of science including his own field - solid-state physics. The second part talks about Anderson's reminiscences and thoughts on his scientific peers, mostly in the form of book reviews that he has written for various magazines and newspapers. The third part deals with science policy and politics and the fourth is dedicated to "attempts" at popularizing science.
Some of the chapters are full of scientific details and can be best appreciated by physicists but there's also a lot of fodder for the layman in here. A running thread through several essays is Anderson's criticism of ultra-reductionism in science which is reflected in the title of the book, "More and Different". Anderson's basic viewpoint is that more is not just quantitatively but qualitatively different from less. In 1972 he made a splash by discussing in an article in Science magazine how "higher-level" sciences are based on their own fundamental laws which cannot be reduced to physics. In the book he details this philosophy through several examples from physics, chemistry, biology and psychology. He does not deny the great value of reductionism in the development of modern science but he incisively explores its limits.
Other chapters contain critiques of the latest fads in physics including string theory. Anderson bemoans string theory's lack of connection to concrete experiment and its failure to predict unique, robust solutions. He makes it clear that string theory is really mathematics and that it fails to adhere to the tried and tested philosophy of science which has been successful for almost five hundred years. Other chapters have insightful commentary on the role of mathematics in physics, Bayesian probability and physics at Bell Labs. A particularly amusing essay critiquing the current funding situation in the United States proposes a hypothetical alternative history of quantum mechanics in the US, where scientific pioneers like Dirac and Heisenberg may not have been able to do groundbreaking research because of the publish-or-perish environment and the dominance of the old guard.
There's also some valuable material in here about the sociology of science. This is exemplified by an especially insightful and detailed chapter on scientific fraud where Anderson explores the reasons why some scientists commit fraud and others don't expose it as widely as they should. In Anderson's opinion the most valuable method to expose fraud is to ask whether it destroys what he calls the "seamless web of science" - the existing framework of fundamental laws and principles that allow relatively little room for revolutionary breakthroughs on a regular basis. In many cases the web's integrity is clearly not consistent with the new finding, and the rare case where the web can subsume the new discovery and still stay intact leads us into genuinely new scientific territory. He also takes scientists to task for failing to point out the destruction of this seamless web by apparently far-reaching but fundamentally flawed new discoveries. In other chapters Anderson also comes down hard on the postmodernism distortion of science, critiquing such philosophers as Nancy Cartwright and upholding the views of debunkers like Alan Sokal. He also has some valuable commentary on science policy, especially on Star Wars and missile defense. Other writers have written much more detailed critiques of such programs, but Anderson succinctly demonstrates the limitations of the concept using commonsense thinking (The bottom line: Decoys can easily foil the system and a marginal improvement by the offense will result in a vastly increased cost for the defense).
Finally, the book contains mini sketches of some of Anderson's peers who happened to be some of the great scientific minds of the twentieth century. Anderson reviews books by and about Richard Feynman, Murray Gell-Mann, Stuart Kauffman, Stephen Hawking, Roger Penrose, John Bardeen and William Shockley among others. I happen to agree with him that books by scientists like Hawking, Penrose and Greene, while fascinating to read, paint a rather biased picture of physics and science. For one thing, they usually oversell the whole reductionist methodology in their constant drive to advertise the "Theory of Everything". But more importantly, they make it sound like particle physics and cosmology are the only games in town worth thinking about and that everything else in physics is done on the periphery. This is just not true. As Anderson makes it clear, there are lots of fields of physics including condensed matter physics, biophysics and non-linear dynamics which contain questions as exciting, fundamental and research-worthy as anything else in science. As just one example, classical physics was considered a staid old backwater of the physics world until chaos burst upon the scene. It's also clear, as was the case with chaos, that some of the most exciting advances will come from non-physicists. There are foundational phenomena and rich dividends to be mined from the intersection of physics with other fields in the twenty-first century.
Anderson's book might precisely be the kind of writing ignored by the public because they are too taken with the Hawkings, Greenes and Randalls. To those folks this volume would be an essential and healthy antidote. There's something in there for everyone, and it makes it clear that science still presents infinite horizons on every level. After all, more is different.
The Sheri Sangji accident: The experimental details
Will quantum physics help us cure Alzheimer's disease?
There's an interesting bit of writing out in the journal ChemMedChem by Jean-Louis Kraus, a medicinal chemist in France who has worked on drug discovery for Alzheimer's disease. The article is essentially a summary of Kraus's pessimistic outlook towards current therapies and approaches addressing Alzheimer's disease. Kraus has worked for a long time in medicinal chemistry and his words reflect experience and not just opinion. The article starts off with some well-founded skepticism but ends up sounding...let's say a little questionable.The theories behind black holes generally suggest that subatomic particles (electrons, protons, neutrons) are themselves black holes, in which time expands in the opposite direction of our proper (perceived) time. Huge amounts of information could be stored by the spin number of photons present in these particle black holes. Could it be possible that the organization of brain matter, in terms of the properties of subatomic particles (quantum mechanics), confers on brain matter the capacities of memory and cognition, and that these phenomena are not encountered in other types of matter structure in the human body?
Come again? I was not familiar with electrons, protons and neutrons being black holes. But even if they are, I fail to see their direct relevance to understanding memory and cognition. Sure, it's a trivial fact that it's a very specific organization of subatomic particles that leads to a brain rather than to a liver or a chair. But the real action all takes place at the level of aggregates of these particles which we call molecules. I get the feeing that Kraus is indulging in a classic reductionist fallacy here. While subatomic particles do constitute the brain, understanding the brain can only come at a higher level, that of rather old-fashioned physics and chemistry involving ionic currents and neurotransmitters.
But Kraus finds a valuable place for quantum physicists in the war on neurodegenerative disorders:
To me it has become mandatory to create an AD scientific community that includes not only medicinal chemists, pharmacologists, biologists, and medical doctors, but also quantum physicists, in order to understand how aging alters the intimate structure of brain matter, where memory and cognition are located, with the hope of finding new AD treatment research orientations.
To me this sounds suspiciously like Roger Penrose's argument in his rather startling book "Shadows of the Mind" in which he postulated a relationship between wavefunction superposition in quantum mechanics and the growth and shrinkage of microtubules as significantly contributing to consciousness. Even a cursory look at that argument raised serious doubts about the relevance of quantum behavior in microtubules and more formal analysis seemed to confirm these doubts. I am not saying that physicists won't be a valuable asset on a drug discovery team, it's just that they are probably not going to use the tools of quantum gravity to map out cognitive pathways anytime soon.
Somewhat ironically, Kraus ends his piece by extolling the role of a systems biology approach in addressing a problem as complex as Alzheimer's disease. With this I wholeheartedly agree, but systems biology is the opposite of reductionism, where new emergent phenomena provide causal explanations that cannot be reduced to the laws underlying their substrates. We do need a suite of analytical tools operating at various hierarchical levels to address the issue, but given enough time and smart people, we should be able to do the job using standard chemistry and biology, albeit at a more sophisticated level. No fancy biophoton entanglement may be necessary.
Kraus, J. (2011). Why as a Medicinal Chemist I Am Not Optimistic about the Possibility of Finding, in a Reasonable Timeframe, Small-Molecule Drugs Capable of Curing the Evolution of Alzheimer’s Disease ChemMedChem DOI: 10.1002/cmdc.201100431
Introverts, extroverts and modern science
Fraud in a glass of wine
One of the biggest stories in biomedical research during the last decade has been the discovery that certain molecules can mimic the effect of what's called caloric restriction, the reduced consumption of calories, either by starvation or by deliberation. Caloric restriction in turn has been linked quite reliably to a slowdown in aging and a general improvement in metabolism in lower animals like, yeast, fruit flies and certain worms. What was particularly alluring was that these effects seemed to be mediated by a single family of genes through proteins called sirtuins. The implication was clear; not only did we have a handle on a significant component of the genetic basis of aging but we could also potentially mimic the effects of anti-aging genes by drugs that targeted sirtuins.But what really catapulted the story to public attention was the finding that resveratrol, a molecule found in red wine, might do this. The presence of a (relatively) cheap edible substance, universally consumed, savored and culturally revered that might slow down aging naturally led to unprecedented public attention. The French and Italians might say "I told you so", but suddenly the holy grail of medical science seemed to be within reach. As usual though, the initial euphoria gradually gave way to a more cautious and tempered belief in the benefits of red wine in mitigating the ill effects of age, and indeed in the whole field of caloric restriction itself. The complete story is fascinating and too convoluted to recount here, but the simple fact of the matter is that the biology of aging is much more complex than we imagined and the initial breakthroughs have not been as unambiguous as they seemed. Not surprisingly, ascribing something as complex as aging and its attendant physiological changes to the action of a single family of genes and proteins has turned out to be simplistic at best (as a comparison, even obesity is thought to be caused by dozens of genes with overlapping effects). In addition, anti-aging effects that got the attention of the New York Times turned out to be significant only in "lower" animals and not in mammals. As it stands today, while research on caloric restriction undoubtedly has great potential, many complications need to be ironed out before the initial optimism can be justified. Curiously, much of the high-profile work in the area can be traced in various forms to a single laboratory at MIT. A recent article in Science does a great job detailing the personalities, the findings and the controversies that sprang from this and other laboratories' work; the entire saga seems fit for a Sinclair Lewis novel.
But whatever the scientific status of the field, its high-profile nature and its potentially revolutionary implications promised ample funding for interested researchers, and over the years it has attracted both highly visible as well as lesser known scientists. One of the individuals who waded into resveratrol territory was Dipak Das of the University of Connecticut Medical School. Over the last few years Das published several papers detailing the beneficial effects of resveratrol in possibly preventing or mitigating oxidative damage caused in cardiovascular and neurological diseases. While most of his research has been published in low-impact journals, it seems that Das was on his way to a lucrative research career involving resveratrol and its role in health and disease.
Until now. It seems that somewhere along the road, he started committing fraud on a massive scale, the likes of which haven't been seen in some time in biomedical research. It started when an anonymous tipster tipped off the university about fabrication in some of Das's papers. The university then launched its own probe and formed a review committee. For the past two years the committee has been working in the shadows with the Office of Research Integrity (ORI) and last week they released their findings in a 50-page document. The findings indicate wholesale fraud, manipulation of results and deliberate doctoring of critical data on a shockingly regular basis between at least 2002 to 2009.There are two aspects of the report that bear closer scrutiny. One is the sheer number of Western blots found to have been doctored. The committee examined 26 papers and cited no less than 88 figures which appear to be manipulated (there were also several that appeared normal). This is a staggering amount of manipulation and rules out accidental oversight. Das would have to be involved in a conscious, deliberate and extended effort to tamper with so much data. It's quite clear that the magnitude of the manipulation alone points strongly to purposeful fraud.
The second aspect of the report concerns the great difficulty of detecting the fraud. Western blots seem to be notoriously amenable to manipulation; for instance they prominently featured in another recent high-profile case of fraud in India involving a researcher at the National Center for Cell Science (NCCS). In the report on Das's work, single bands of proteins in Western blots have been enlarged and their borders further magnified to show the contrast between the background for that particular band and for others, indicating that the band in question was copied and pasted. Image manipulation software can sometimes produce such artifacts and some of the data appears like it could also have been the result of negligence or sloppy editing, but the number of such instances again rules out merely these possibilities.The debacle is ending in ways that such unfortunate scenarios usually end. The university has already begun proceedings to fire Das from his position. It is very likely that he will never be able to do research again, and that's probably the way it should be given the extent of his fraud. Sadly, Das has not made things any easier by accusing university and department officials of racist prejudice. When you have to resort to such allegations in the face of massive evidence detailing your dishonesty, you only make your guilt seem more likely.
Ultimately this episode speaks as much about the culture of scientific research as it does about the transgressions of a particular researcher. We may not know for some time why Das felt like committing fraud on such a massive scale, but I suspect that the high-profile nature of anti-aging research and the funding that such research commands may have had at least something to do with it. In the last few years, resveratrol, caloric restriction and sirtuins have made it into the public discourse about science like few other topics. The possibility of harnessing all this data to solve the ultimate mystery of aging has ensured both sensationalist news items and eager funding agencies wanting to enable the next breakthrough. When you work in such high-profile fields, it is more tempting to fabricate your results to snare more funding. In this particular case, Das's work was deemed to be low-impact and peripheral to the field and so the damage might be negligible, but in someone else's hands it could well be extensive. The case of Jan Schon immediately comes to mind.The only remedy for avoiding such debacles may be more acute vigilance, self-policing and an honest willingness to accept failures. And some modesty before nature may be in order here.
Other coverage: Derek Lowe (1, 2), San Francisco Chronicle
What is your favorite deep, elegant or beautiful explanation (in chemistry)?
Over at Edge, they have a survey asking leading scientists, thinkers and writers about what they think is their favorite "elegant, deep or beautiful explanation". This is meant to be a very general question, not even limited to science and includes responses from people as diverse as the economist Richard Thaler, complexity theorist Stuart Kauffman and Stewart Brand (founder of the Whole Earth Catalog). The answers include ideas, explanations, experiments and entities as general and diverse as the scientific method, genes, Pascal's wager, bounded rationality, relativity and the limits of intuition.The explanations run across the gamut of the sciences and the humanities including physics, biology, economics, neuroscience, politics and business. But conspicuously absent is chemistry, except for a few peripheral references like Charles Simonyi's listing of Besicovitch's theory of atomic forces. And this is in spite of our friend Derek Lowe of "In the Pipeline" being included in this august list. I was gratified to see a chemist being asked for his opinion, and was somewhat disappointed that Derek's favorite explanation was not chemical (his favorite is the rather deceptively simple notion of "freefall"). I of course don't blame Derek for his choice since there is no law dictating that a chemist's favorite explanation should be from chemistry just because he or she is a chemist. My own favorite beautiful explanation is probably Cantor's notion of multiple infinities.
But I did regret the striking omission of chemistry from the list. Sometime back I had a whole post on elegance in chemistry. And I certainly don't want people to think that deep and elegant explanations are limited to physics and biology, because they are not. Chemistry may not boast of profound philosophical explanatory frameworks like the Big Bang or evolution by natural selection. But it makes up for this fact by creating paradigms that directly touch the lives of millions of human beings in ways much more palpable than the Big Bang and evolution. So I thought I would add my own modest thoughts on my favorite deep idea in chemistry.
There's actually a few things at the top of my list; you certainly don't have to think hard to come up with several foundational chemical ideas. But if you really asked for my absolute favorite deep and elegant explanation, it is the shared-electron chemical bond. That's it. Right there is the simple concept that is at the heart of the material world, a concept that if you think about it has had a staggering impact on our quality of life, our relationships with other nations, our notion of prosperity itself. Chemical bonds as manifested in the foundations of modern civilization have certainly contributed as much to life, liberty and the pursuit of happiness as any scientific idea.
The idea itself as formulated by the great Gilbert Newton Lewis and comprehensible to any high-school student is simplicity incarnated; atoms combine into molecules and form a bond when electrons are shared. Everything that comes after the stating of this fact, important as it is, is details. All the quantum chemical wizardry, the thinking-in-orbitals, the great Gaussian simplification, it's after this basic groundwork has been laid. Heitler and London, Pauling, Slater, Mulliken, Pople, all of them made critical contributions to chemical bonding, but they all stood on Lewis's shoulders and built up from his landscape of the shared electron chemical bond.
Given the absolutely foundational role that the chemical bond plays in the thinking of chemists, it may be both ironic and a tad disturbing that chemists still cannot completely agree on the precise definition of every molecular bond out there. But that's not because the basic framework underlying bonding is uncertain. Part of the reason is simply because there is no such thing as "the" chemical bond. The bonding zoo sports a bewildering variety of animals, from the upstanding "normal" chemical bonds in, say the hydrogen or methane molecules, to the (literally) ready-to-snap pressure cooker entities in strained organic compounds, from the wily, shape-shifting bonds between metals and organic compounds to the ephemeral but biologically vital hydrogen bonds. Although the basic theory of the chemical bond is securely in place, it's going to take some time to craft a net wide and yet rigorous enough to snare the unruly and colorful creatures dotting the chemical landscape.
Now physicists may try to appropriate the chemical bond as their own, but they are out of luck. No explanation based purely on physics can truly impart a feel for the sheer diversity of bonds quoted above and their context-specific personalities. Just one bond serves to create a nightmare for purely reductionist approaches to defining chemical bonding- the hydrogen bond. Last year chemists convened at a meeting with the express purpose of tweaking their description of this all-important biological mediator, the glue that holds life together. Several questions were bandied about, but none more important than the very definition of a hydrogen bond. The problem was simple; hydrogen bonds can be weak or strong, sometimes so weak as to strain the definition of a bond, sometimes strong enough to suspiciously qualify as a covalent bond. How much of hydrogen bonding is electrostatic and how much is covalent? Is "bond" even the right term, or would "bridge" be more accurate? How do you define hydrogen bonds to metals? A consensus was finally reached on a new definition, but not even Linus Pauling could say that the definition would hold for all of eternity. Defining a hydrogen bond would give every physicist out there a run for his money. I find the concept of the chemical bond so enticing and elegant partly because even a single kind of bond like the hydrogen bond can hide a richly textured world of possibilities lurking behind its surface.
So there it is, why the concept of the chemical bond is my favorite idea, certainly in chemistry. It is deep because it underlies the making of the material universe, explaining the stuff that everything from crab shells to the Crab Nebula is made of. It is elegant because of the virtually unlimited amount of explanatory power that it hides in a simple statement of definition. And it is beautiful because of the sheer diversity of materials and structures that are created from a simple law of attraction. A lot of the thinkers in the Edge survey quoted evolution as their favorite deep idea. It certainly is beautiful. But Darwin could well have slightly paraphrased his words to apply to Lewis's shared-electron chemical bond:
"There is grandeur in this view of the material world, with its several powers, having been originally breathed into a single bond; and that, whilst this planet has gone cycling on according to the fixed law of gravity, from so simple a bond endless forms most beautiful and most wonderful have been, and are being, evolved."
Molecular modeling: How far can physics take us?
Of all the scientists writing about modeling and simulation in drug discovery in the last decade or so, I have found Anthony Nicholls of OpenEye Scientific Software to be one of the most insightful. Not only has he written important papers emphasizing the role of rigorous statistics in generating and communicating modeling results, but he has also been a relentless proponent of the need for rigorous, unglamorous but essential experimental data to validate modeling protocols. In the phalanx of modelers pointing to a better future for their field, Anthony has been one of the torchbearers. I usually pay close attention when he writes so I think it's worth noting what he has to say in a recent article titled "The character of molecular modeling".He starts by asking what the real advances in the field have been in the past 25 years and by observing an apparently rather disconcerting fact about modeling and especially structure-based modeling - successes are still mainly anecdotal. He expresses his disappointment while noting that most of the successful results in modeling are still mainly of the "find protein pocket, fill pocket" type. The chief role of the crystallographer, it seems, is to supply pockets that the computational chemist can then fill. The problem according to Anthony is that chemists are not "abstracting principles of wide applicability; they are recognizing domains of expertise".
At this point let me interject and say that while Anthony's gloomy prognosis might be true, it's also true that "find pocket, fill pocket" (or "find pocket, kill pocket" if you are in a hunter-gatherer mood) campaigns are not as straightforward as we think. There can be unexpected effects on both protein conformation and ligand conformation, similar to the "activity cliffs" witnessed by medicinal chemists. Even if the binding orientation of the ligand stays constant upon small changes, the distribution of solution conformations of the modified ligand is likely quite different, leading to differing energetic penalties that the protein has to pay for binding. I am sure I am not alone in saying that small changes in ligand structure leading to changes in binding affinity enforced by ligand strain and conformation are uncomfortably frequent. But there's another dimension to the "find pocket, fill pocket" campaign; it can actually be quite satisfying to suggest changes to a medicinal chemist for filling the pocket that are borne out by further crystallography. Finding pockets may generate anecdotes, but chemistry is a more anecdotal science than say physics, and chemists often revel in these little successes and failures. Chemists are more frogs than eagles.
But the real sticking point for Anthony is not really the anecdotal success of structure-based modeling but the lack of general physics-based principles and laws for doing molecular modeling. Docking is an example. In the last several years there have been many attempts to use physics-based "scoring functions" - essentially ways to sum up different protein-ligand interactions to a number - for calculating the binding affinity of a ligand. Programs for docking have evolved to a stage where ligands can be docked in the correct orientation with a roughly 30% success rate, depending on how similar the docked ligands are to a reference co-crystallized ligand. But the truth of the matter is that we still fail miserably when trying to dock an arbitrary ligand to an arbitrary protein in an arbitrary conformation. And of course, we are light years away from predicting free energies of binding for the general case. There have been cases in which physics in the form of electrostatics and quantum mechanics (more on this later) has significantly accelerated the search for similar molecules, but the promised land still seems far.
Does this failure reflect an absence of general principles of physics for computing protein-ligand interactions? Paraphrasing Rutherford (not Niels Bohr), in the next few decades will we do more physics or simply collect more stamps? Is this concern even warranted? To some extent, yes. It would certainly be very satisfying to have a general explanatory framework, a pool of more or less universal laws that explained the wide variety of protein-ligand complexes as completely as Newton's laws explain the behavior of an astonishingly diverse set of particle interactions in the classical world. Curiously, such a general framework does exist in the form of statistical mechanics and quantum mechanics. In theory, both these disciplines encompass the binding of every single protein to every single drug. So does that mean we can look forward to a time when every modeler can "abstract these principles of wide applicability" and use them to solve the particular case of his or her protein and ligand?
Here is where I part ways with Anthony at least partly. The reason in my mind is not too hard to discern. Think about how far we have come in explaining protein-ligand binding using the rather extensive developments in either quantum or statistical mechanics over the past five decades. The answer is, not as far as we would have liked to. While we have indeed made great advances in understanding the basic thermodynamics of protein-ligand binding, we have not been very successful in incorporating these principles into predictive computational models. Why so? For the same reason that we have not been successful in using physics to explain "all of chemistry", in Paul Dirac's words. Quantum mechanics has been applied to chemistry for fifty years and exponentially increasing computational power has significantly furthered its application, but even now, for most practical systems chemists use a variety of empirical models to understand and predict. That's partly because most real systems are too complex for the direct use of quantum mechanics, and an imperfectly understood protein and ligand immersed in an imperfectly understood solvent certainly belong to this category. It's also because we are still far from calculating things like entropy and being able to model the differential behavior of water at interfaces and in the bulk.
But even more importantly, physics may not solve our problems because chemists need to abstract general principles at the level of chemistry to ply their trade. Thus, in expressing doubts about the utility of general physics-based principles, I am appealing to the strong sense of non-reductionism that permeates chemistry and separates it from physics. The same principle applies to biology and I have written about this often. Principles drawn from physics have always been very useful in gaining insights into molecular interactions and they will continue to be an essential part of the mix. But unlike Anthony, I see a far smaller role that pure physics can truly make in enabling a general, practical predictive approach to modeling that's "chemical" enough to be widely used by chemists.
So are there cases in which physics can make a contribution? Here I actually do agree with Anthony when he mentions two areas where physics really promises to have a substantial impact, both conceptually and practically. The first is crystal structure prediction for organic molecules which is a notoriously fickle problem (a measure of the difficulty can be gleaned by the fact that even the simple benzene can crystallize in more than 30 different geometries), essentially one of being able to predict fine energy differences between almost equienergetic arrangements. Yet I see this problem as one of the more reductionist problems in chemistry, and as Anthony notes, it is conceivable that it will yield to physics-based approaches in the near future.
The other problem is one of the holy grails of chemistry and biology - protein structure prediction. In various guises, the last few years have seen a startlingly impressive set of cases where protein structures of small and (some) medium-sized proteins were predicted with atomic level accuracy. Protein structure prediction has to overcome the twin challenges of sampling and energy estimation that are a mainstay of almost every other modeling method. In this case Anthony thinks that we will have to get the physics right to address this issue.
But we have to be careful to distinguish between two cases here. The first case is where we get the right structure even if we have no idea how we got there. This is the field of empirical (non-physics based) protein fold prediction and the biggest success in this area has been the ROSETTA suite of programs. ROSETTA has definitely turned heads within the community by its ability to generate accurate structures for hundreds of proteins, but the big drawback of the approach is that it only generates the end result. Curiously Anthony does not mention ROSETTA, but I am also surprised that he does not mention in detail another significant development that does fit into the physics-based paradigm. This is the molecular dynamics approach developed by David Shaw, Vijay Pande and others. Unlike ROSETTA, MD can actually shed light on the process leading to a correct structure, although the details of the process are subject to errors, most notably in the force fields that underlie the simulation. It's quite clear that with all their limitations, ROSETTA and MD have been the biggest contributors to successful protein folding simulations over the last decade.
And yet as Anthony rightly says, their success seems almost like a miracle. This becomes clear when we realize that even now we have trouble predicting something as simple as the solvation energy of a simple organic molecule or the interaction energy of two simple molecules using even sophisticated quantum mechanics calculations. If our ability to predict even such simple scenarios is dismal, how on earth are we getting the structures of all those complex proteins right? The answer deserves as much scrutiny as the solution to these problems, scrutiny that is severely lacking. Anthony's answer (and mine) is "cancellation of errors along with a need to calculate only relative, not absolute, energies" (it's well known that force fields are virtually worthless for the calculation of absolute energies). It still strains my mind to think that these two factors could contribute to so many successful predictions published in the likes of Nature and Science. Cancellation of errors was partly made famous by Enrico Fermi. If that's really what's happening in all these cases, then the entire field needs to start celebrating Fermi as their guardian angel.
Ultimately, there is no doubt that advances will continue to be made with increasing computational firepower, but the foundations of the field will stay brittle unless these fundamental issues are addressed. Anthony ends with something he has been doing for a long time now - appealing to experimentalists, industry and government to contribute a small part of their funds to the kind of basic experiments that can further the field of modeling. This especially involves experiments that can refute an idea, a philosophy that has been dominant in the practice of science since its modern conception but one which seems to be unusually neglected in drug discovery because of the emphasis on positive data gathering. Science has always progressed by the testing of ideas that have no immediate practical bearing, except that they perform the invaluable function of making future scientific research worthwhile. It would be fundamentally unscientific if such ideas are not supported. Anthony puts it well:
"The simple commitment to spend a small percentage of the science budget at the NIH or at pharmaceutical companies on nontranslational work, providing support for the small cabals of scientists actually interested in making fundamental progress would be enormous. Reestablishing the contact between theorists and experimentalists, the publishing of high quality data, conferences devoted to the actual testing of ideas—in 25 years we might hope molecular modeling could become a real scientific discipline."